Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

Go back to Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
(NASDAQ: PGEN) Delayed: 6.87 -0.23 (3.24%)
Previous Close $7.10    52 Week High
Open $6.89    52 Week Low
Day High $7.02    P/E N/A 
Day Low $6.72    EPS
Volume 2,770,580